NASDAQ:TYME

Tyme Technologies - TYME Stock Forecast, Price & News

$0.31

+0.02 (+7.83%)

(As of 09/16/2022)

Add

Compare

Today's Range: $0.29
▼
$0.33
50-Day Range: $0.24
▼
$0.35
52-Week Range: $0.22
▼
$1.14

Volume: 67,913 shs
Average Volume: 1.01 million shs
Market Capitalization: $53.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Tyme Technologies (NASDAQ:TYME) Stock

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

TYME Stock News Headlines

September 27, 2022 | marketwatch.com

Thymol Market Expected to Raise at 2.36% CAGR by 2022-2027 | 123 Report Pages

September 15, 2022 | marketwatch.com

Syros, Tyme Technologies Shares Rise After Hldrs Approve Merger

September 15, 2022 | finance.yahoo.com

Syros and Tyme Technologies Announce Stockholder Approval of Merger

September 7, 2022 | it.tmcnet.com

TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote "FOR" Proposed Merger of Syros and Tyme

September 7, 2022 | finance.yahoo.com

TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme

August 26, 2022 | msn.com

Moderna Throws First Jab, Files Lawsuit Against Pfizer Over Use of ‘Patented’ COVID-19 Vaccine Technology

August 26, 2022 | msn.com

Moderna sues Pfizer for allegedly copying its COVID-19 vaccine technology

August 26, 2022 | msn.com

Moderna Sues Pfizer Over COVID-19 Vaccine Technology

August 19, 2022 | marketwatch.com

Herbs & Spice Extract Market foreseen to grow exponentially over 2029 with Impressive CAGR| Exclusive Report Spread Across 119 Pages

August 9, 2022 | seekingalpha.com

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2022 Results - Earnings Call Transcript

August 9, 2022 | msn.com

How to repel wasps from your garden as UK set for invasion

August 4, 2022 | bizjournals.com

Most Influential Business Women 2022: Joan Daleo guides Ole Tyme Produce to new growth

July 27, 2022 | finance.yahoo.com

AmeriHealth New Jersey and Thyme Care Collaborate to Support Members in Navigating their Cancer Journey

July 21, 2022 | apnews.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, SYRS, SIMO

July 12, 2022 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Reminds SYRS, CNVY, RADA, and SIMO Shareholders About Its Ongoing Investigations

July 5, 2022 | marketwatch.com

Syros Pharma to Merge with Tyme Technologies

July 5, 2022 | benzinga.com

Investor Alert - The M&A Class Action Firm Announces an Investigation of Tyme Technologies, Inc. - TYME

July 5, 2022 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether TYME Technologies, Inc. has obtained a Fair Price in its transaction with Syros

July 5, 2022 | marketwatch.com

Tyme Technologies Shares Soar on Syros Merger

July 5, 2022 | nasdaq.com

Syros Pharmaceuticals To Acquire TYME Technologies

July 5, 2022 | finance.yahoo.com

Syros to acquire New Jersey biotech Tyme Technologies

July 1, 2022 | bizjournals.com

Future of Cancer Care: Thyme Care is making treatment, life easier for patients

June 28, 2022 | nz.finance.yahoo.com

Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer

June 23, 2022 | msn.com

A Short History of the American Lawn

June 21, 2022 | msn.com

How To Complete The Broken Flowers Quest In The Witcher 3

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

TYME Company Calendar

Last Earnings: 8/09/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TYME
CUSIP: N/A
CIK: 1537917
Web: www.tymeinc.com
Phone: (212) 461-2315
Fax: N/A
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -28.30%
Return on Assets: -26.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.06
Quick Ratio: 14.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.47 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 172,207,000
Free Float: 143,104,000
Market Cap: $53.38 million
Optionable: Optionable
Beta: 0.93

Key Executives

Mr. Richard Cunningham (Age 51)
CEO & Director
Comp: $789.9k

Mr. Steven E. Hoffman (Age 59)
Co-Founder & Director
Comp: $2.6M

Mr. Frank L. Porfido (Age 58)
Chief Financial Officer
Comp: $488.2k

Mr. James Biehl J.D. (Age 58)
Chief Legal Officer & Sec.
Comp: $635.89k

Dr. Jonathan M. Eckard (Age 48)
Chief Bus. Officer

Dr. Jan Marie-Albert Van Tornout M.D. (Age 66)
M.Sc., Acting Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TYME Stock - Frequently Asked Questions

How have TYME shares performed in 2022?: Tyme Technologies' stock was trading at $0.6031 at the beginning of the year. Since then, TYME stock has decreased by 48.6% and is now trading at $0.31.
View the best growth stocks for 2022 here.
When is Tyme Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TYME earnings forecast.
How were Tyme Technologies' earnings last quarter?: Tyme Technologies, Inc. (NASDAQ:TYME) announced its earnings results on Tuesday, August, 9th. The company reported ($0.04) earnings per share for the quarter.
What other stocks do shareholders of Tyme Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?: Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
How do I buy shares of Tyme Technologies?: Shares of TYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tyme Technologies' stock price today?: One share of TYME stock can currently be purchased for approximately $0.31.
How much money does Tyme Technologies make?: Tyme Technologies (NASDAQ:TYME) has a market capitalization of $53.38 million. The company earns $-23,630,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.
How can I contact Tyme Technologies?: Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The official website for the company is www.tymeinc.com. The company can be reached via phone at (212) 461-2315 or via email at investorrelations@tymeinc.com.

This page (NASDAQ:TYME) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms